(Q41637147)

5 October 2017

1 reference

title

Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers (English)

1 reference

5 October 2017

1 reference

1

1 reference

5 October 2017

1 January 1997

1 reference

5 October 2017

1 reference

5 October 2017

54 Suppl 4

1 reference

5 October 2017

22-29

1 reference

Future of cancer chemotherapy with cisplatin

5 October 2017

1 reference

12 December 2020

Cytoprotection: concepts and challenges

1 reference

12 December 2020

Liposomes. Opportunities in drug delivery

1 reference

12 December 2020

Key issues in the treatment of advanced breast cancer. Expectations and outcomes

1 reference

12 December 2020

High-dose chemotherapy with peripheral blood progenitor autografting

1 reference

12 December 2020

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

12 December 2020

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

1 reference

12 December 2020

High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial

1 reference

12 December 2020

A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer

1 reference

12 December 2020

Response to dexamethasone in patients with fluid retention after docetaxel

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

12 December 2020

Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels

1 reference

12 December 2020

Managing breast cancer in an outpatient setting

1 reference

12 December 2020

Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma

1 reference

12 December 2020

Salvage chemotherapy for epithelial ovarian carcinoma

1 reference

12 December 2020

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

12 December 2020

Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications

1 reference

12 December 2020

Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.

1 reference

12 December 2020

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

12 December 2020

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

1 reference

12 December 2020

Quality of life as an outcome in breast cancer. Clinical application

1 reference

12 December 2020

Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin

1 reference

12 December 2020

Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol

1 reference

12 December 2020

Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums

1 reference

12 December 2020

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

1 reference

12 December 2020

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

12 December 2020

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

1 reference

12 December 2020

Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.

1 reference

12 December 2020

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

12 December 2020

What have we achieved in ovarian cancer? A comparison of survivals and resources in two different periods

1 reference

12 December 2020

Activity of anthracyclines in refractory ovarian cancer: recent experience and review

1 reference

12 December 2020

10.2165/00003495-199700544-00006

Identifiers

DOI

0 references

PubMed ID

9361958

1 reference

PubMed ID

9361958